Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one‐day versus seven‐day symptom reporting
Crossref DOI link: https://doi.org/10.1177/2045894020923957
Published Online: 2020-05
Published Print: 2020-04
Update policy: https://doi.org/10.1177/sage-journals-update-policy
Frantz, Robert P.
Chin, Kelly M. http://orcid.org/0000-0002-1214-6723
Zhao, Carol
Flynn, Megan
Badesch, David
Funding for this research was provided by:
Actelion Pharmaceuticals
Actelion Pharmaceuticals US Inc, South San Francisco, California
Version of Record valid from 2020-05-01
License valid from 2020-04-01